Comparing predictors of conversion to alzheimer's disease using the disease state index

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 200-202

  Muñoz Ruiz, Miguel Ángel ^a   Hall, Anette ^a   Mattila, Jussi ^c   Koikkalainen, Juha ^c   Herukka, Sanna Kaisa ^a,b   Vanninen, Ritva ^b   Liu, Yawu ^a,b   Lötjönen, Jyrki ^c   Soininen, Hilkka ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Magnetic resonance imaging; Mild cognitive impairment; Positron emission tomography

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE STATE INDEX; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALZHEIMER DISEASE NEUROIMAGING INITIATIVE; CEREBROSPINAL FLUID; CONFERENCE PAPER; CONTROLLED STUDY; DEMENTIA ASSESSMENT; NERVOUS SYSTEM PARAMETERS; PREDICTION; VOLUMETRY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84896900103     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000354074     Document Type: Article

References (10)

1. Dubois B, Feldman HH, Jacova C, et al: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
2. Mattila J, Koikkalainen J, Virkki A, et al: A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis 2011; 27: 163-176.
3. Mueller SG, Weiner MW, Thal LJ, et al: The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005; 15: 869-877, xi-xii.
4. Landau SM, Harvey D, Madison CM, et al: Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-238.
5. Schuff N, Woerner N, Boreta L, et al: MRI of hippocampal volume loss in early Alzheimer's disease in relation to APOE genotype and biomarkers. Brain 2009; 132: 1067-1077.
6. Hua X, Hibar DP, Ching CR, et al: Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage 2013; 66: 648-661.
7. Vos S, van Rossum I, Burns L, et al: Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012; 33: 2272-2281.
8. Mattsson N, Zetterberg H, Hansson O, et al: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
9. Liu Y, Mattila J, Ruiz MA, et al: Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted Predict AD tool. PLoS One 2013; 8:e55246.
10. Shaffer JL, Petrella JR, Sheldon FC, et al: Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013; 266: 583-591.